Neumora Therapeutics (NMRA) Earnings Date, Estimates & Call Transcripts $10.84 -0.85 (-7.27%) (As of 11/15/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Neumora Therapeutics Latest Earnings SummaryUpcoming Q4 Earnings DateMar. 6EstimatedActual EPS (Nov. 12) -$0.45 Missed By -$0.06 Consensus EPS (Nov. 12) -$0.39 Neumora Therapeutics announced Q3 2024 earnings on November 12, 2024, reporting an EPS of -$0.45, which missed analysts' consensus estimates of -$0.39 by $0.06. With a trailing EPS of -$1.87, Neumora Therapeutics' earnings are expected to decrease next year, from ($1.58) to ($1.61) per share. Conference Call TranscriptConference Call AudioNMRA Upcoming EarningsNeumora Therapeutics' next earnings date is estimated for Thursday, March 6, 2025, based off prior year's reporting schedules. Get Neumora Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neumora Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataNMRA Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.NMRA Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Porter & CompanyThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. Neumora Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241-$1.56-$1.56-$1.56Q2 20241-$1.59-$1.59-$1.59Q3 20242-$0.38-$0.33-$0.36Q4 20242-$0.46-$0.46-$0.46FY 20246-$3.99-$3.94-$3.97Q1 20251-$0.47-$0.47-$0.47Q2 20251-$0.48-$0.48-$0.48Q3 20251-$0.49-$0.49-$0.49Q4 20251-$0.50-$0.50-$0.50FY 20254($1.94)($1.94)($1.94) Neumora Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 3/6/2025(Estimated)------- 11/12/2024Q3 2024-$0.39-$0.45 -$0.06-$0.45-- 8/6/2024Q2 2024-$0.37-$0.37--$0.37-- 5/7/2024Q1 2024-$0.34-$0.34--$0.34-- 3/7/2024Q4 2023-$0.76-$0.71+$0.05-$0.71-- 11/1/2023Q3 2023-$0.35-$1.14 -$0.79-$1.14-- Neumora Therapeutics Earnings - Frequently Asked Questions When is Neumora Therapeutics's earnings date? Neumora Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 6th, 2025 based off last year's report dates. Learn more on NMRA's earnings history. Did Neumora Therapeutics beat their earnings estimates last quarter? In the previous quarter, Neumora Therapeutics (NASDAQ:NMRA) missed the analysts' consensus estimate of ($0.39) by $0.06 with a reported earnings per share (EPS) of ($0.45). Learn more on analysts' earnings estimate vs. NMRA's actual earnings. How can I listen to Neumora Therapeutics's earnings conference call? The conference call for Neumora Therapeutics's latest earnings report can be listened to online. Listen to Conference Call How can I read Neumora Therapeutics's conference call transcript? The conference call transcript for Neumora Therapeutics's latest earnings report can be read online. Read Transcript How much profit does Neumora Therapeutics generate each year? Neumora Therapeutics (NASDAQ:NMRA) has a recorded net income of -$235.93 million. NMRA has generated -$1.87 earnings per share over the last four quarters. What is Neumora Therapeutics's EPS forecast for next year? Neumora Therapeutics's earnings are expected to decrease from ($1.58) per share to ($1.61) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies Repligen Earnings Halozyme Therapeutics Earnings Arcellx Earnings ADMA Biologics Earnings Krystal Biotech Earnings Denali Therapeutics Earnings Immunovant Earnings CRISPR Therapeutics Earnings ImmunityBio Earnings Kymera Therapeutics Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings ReportPulteGroup Earnings Signal Potential Entry Points for Investors This company will win the AI race (Ad)Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. This page (NASDAQ:NMRA) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
